期刊文献+

异长春花碱持续静脉输注治疗晚期非小细胞肺癌的临床观察

Clinical observation on continuous infusion of home-made vinorelbine with cisplatin for management of advanced or metastatic non-small cell lung cancer
下载PDF
导出
摘要 目的:比较异长春花碱持续静脉输注与常规用法治疗晚期非小细胞肺癌的疗效和毒性。方法:将5 2例晚期非小细胞肺癌患者随机分为治疗组2 5例和对照组2 7例。治疗组采用异长春花碱持续静脉输注给药,对照组采用异长春花碱常规静脉推注给药。结果:治疗组缓解率为4 8.0 %;对照组缓解率为4 4 .4 %,两组比较无显著性差异(P>0 .0 5 )。两组主要毒性反应骨髓抑制、白细胞减少发生率分别为5 2 .0 %和85 .2 %,两组比较有极显著性差异(P<0 .0 1 )。结论:异长春花碱持续静脉输注与常规治疗方法相比,缓解率稍有提高,血液学毒性明显减低,采用锁骨下静脉置管可避免发生静脉炎,降低总的治疗费用,值得临床推广应用。 Objective: To compare the efficacy and toxicity of continuous vinorelbine infusion and conventional use for advanced non-small cell lung cancer (NSCLC). Methods: 52 patients with advanced or metastatic NSCLC were divided into home-made vinorelbine continuously curative group and conventionally curative group.Results: Response rate was 48.0% for the continuously curative group,or 44.4% for the conventionally curative group,showing no significant difference between the groups (P>0.05). As main toxic reaction, neutropenia incidences were 52.0% and 85 2% in the both groups, respectively, showing a significant difference (P<0.01). Conclusion: In comparison with conventional usage, continuous infusion of home-made vinorelbine with cisplatin shows evidently lower toxic reaction although improvement in its response rate is not especially satisfactory. Besides, administration through subclavian venae catheter may not only avoid cheno-phlebitis, but also reduce total curative expense, deserving to be further popularized.
出处 《华夏医学》 2005年第2期160-161,共2页 Acta Medicinae Sinica
关键词 异长春花碱 非小细胞肺癌 持续静脉输注 home-made vinorelbine non-small cell lung cancer continuous infusion
  • 相关文献

参考文献4

二级参考文献16

  • 1潘启超.长春碱类的新进展──失碳长春碱[J].癌症,1996,15(3):228-231. 被引量:276
  • 2管忠震,癌症,1993年,12卷,217页
  • 3张湘茹,北京医学,1992年,14卷,171页
  • 4Le chevelier T, Pujol JL, douillard JY, et al. Six year follow-up the European multicentre randomized study comparing navelbine(NVB) alone VS NVB+cisplatin(CDDP) VS vindesin(VDS)+CDDP in 612 patients with advanced non-small cell lung cancer(NSCLC)[J].lung Cancer,1997,18(Suppl 1):13.
  • 5Antotinette JW, Growley JJ, Balcerzak SP, et al. Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-small cell lung cancer: A southwest oncology group study[J].J Clin Oncol, 1998,16:2459.
  • 6Wozniak AJ, Crowley JJ, Weiss GR, et al. Randomized phase Ⅲ trial of CDDP VS DDP plus NVB in treat of advanced NSCLC. an update of SWOG-9308[J].Proc ASCO, 1998, 435:1744.
  • 7Fellous A, Meininger V, Binet S, et al. Action of navelbine (NVB) on microtubules-Role of Tan and MAP2 proteins. In: Pierre Fabre Oncologie, ed s . Navelbine:update and new trends. 1st ed. France. John Libbey Eurotext Ltd , 1991.9.
  • 8Cros S, Wright M, Morimoto M, et al. Experimental antitumor activity of n avelbine. Semin Oncol, 1989, 16(Suppl 4):15.
  • 9Diana F. Current options in the treatment of non-small cell lung cancer. D rugs 44(Suppl 4), 1992,46.
  • 10Hohneker JA.A summary of vinorelbine (navelbine) safety data from North Amer ican clinical trials. Sernin Oncology, 1994,21(5,Suppl 10):42.

共引文献583

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部